يعرض 1 - 10 نتائج من 73 نتيجة بحث عن '"Shivhare A"', وقت الاستعلام: 1.36s تنقيح النتائج
  1. 1

    المصدر: Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine

    الوصف: Background Coronavirus disease-2019 (COVID-19) commonly presents with respiratory symptoms. However, symptoms involving the digestive system may be present, significance of which is not well studied in the Indian scenario. Methods This prospective observational cohort study included consecutive patients with severe COVID-19 admitted to intensive care unit of our tertiary care hospital from September 9, 2020, to March 14, 2021. We evaluated the frequency of preadmission digestive symptoms and compared the demographic, clinical, laboratory parameters, and organ failure at admission and during intensive care along with mortality between those with and without digestive symptoms. In the digestive group, we sought to find predictors of mortality. Results Digestive symptoms were present in 76/234 (32.4%) with severe COVID-19 infection. In comparison to nondigestive group, digestive patients had higher need for noninvasive ventilation (p 0.028), invasive lines (68%, p 0.003), vasopressors (64%, p 0.01), blood product transfusion (21.1%, p

  2. 2

    المصدر: Turkish Journal of Obstetrics and Gynecology

    الوصف: Episiotomy site hematoma, though uncommon, can be associated with serious maternal morbidity. It arises mostly due to tissue trauma or injury to blood vessels, leading to the formation of a pseudoaneurysm. Sometimes, when surgical management fails, embolization of the bleeding vessel is a lifesaving option. Here, we report two cases of episiotomy site hematoma that required selective arterial embolization for management, following the failure of surgical management. A 28-year-old G6A5 woman underwent forceps delivery following which she developed a 6*6-cm right-sided vulvovaginal hematoma at the episiotomy site. After failed surgical management, arterial embolization was performed and hemostasis was achieved. A 26-year-old P2L2 woman with a history of surgical exploration for episiotomy site hematoma, presented postdelivery on postpartum day seven with profuse vaginal bleeding. Her computed tomography angiogram revealed a pseudoaneurysm of around 2.1*1 cm in length with a vaginal hematoma of 4*5 cm. Selective artery embolization performed and complete hemostasis was achieved with no complications. Selective arterial embolization is a safe therapeutic option for episiotomy site hematoma, especially if surgical management fails.

  3. 3

    المصدر: International Journal of Applied Research. 7:323-328

    الوصف: Introduction: In this period of modernization and fast life, people undergo many unwanted practices like improper sitting posture for long time in offices, continuous work in one posture, over exertion, lack of physical exercise, excessive loads to bearing movements during travelling and sports, all these factors create undue pressure and compressive injury to the spine, that play an important role in producing disease like Cervical Spondylosis. Modern medicine has limited conservative and surgical procedures which provide only temporary symptomatic relief and many times have hazardous side effects. In Ayurveda through its sign and symptoms it can be correlated with Prishtagraha. There is need to explore the Ayurvedic perspective of cervical spondylosis by which we can cure and prevent this disease. Aim & Objective: To study the clinical manifestations, etiological factors, pathogenesis and management of cervical spondylosis through Ayurvedic perspective. Materials and Methods: For this study Ayurveda Samhitas like Charak Samhita, Sushruta Samhita etc, authentic publications, internet and modern medical literature have been reviewed. Conclusion: It is concluded that, on the basis of clinical manifestation, pathogenesis and complication cervical spondylosis can be correlated with Pristha (back of neck) Graha (stiffness or obstruction) and the Ayurvedic treatment modalities can be used as an effective management in cervical spondylosis.

  4. 4
  5. 5
  6. 6

    المصدر: International Ayurvedic Medical Journal. 8:4684-4693

    الوصف: Background: Sciatica is the most common disorder which affects the quality of life of individual. Sciatica is the set of symptoms which is caused by a pinching and /or irritation of one of the three lowest nerve roots that make up the giant sciatic nerve and causing a low back pain and leg pain. Prevalence of sciatica ranges from 2% to 40% worldwide. In Ayurveda sciatica has a high resemblance with Gridhrasi, which comes under Samanyaja Vikara and Nanatmaja Vatavikara. Aim & Objectives: To study the effect of Dashmooladi Niruha Basti with Rasaraj Rasa in the management of Gridhrasi (Sciatica) and to find out an effective Ayurvedic management for Gridhrasi (Sciatica). Material and Methods: An open clinical study with Dasmooladi Niruha Basti with Rasaraj Rasa was done in 10 patients of Gridhrasi (sciatica). 10 clini-cally diagnosed patients of Gridhrasi (sciatica), registered at the Kayachikitsa OPD of Pt. Khushilal Sharma Govt. Ayurvedic Hospital Bhopal. The patients were treated with Dasmooladi Niruha Basti along with Rasaraj Rasa. Duration of study is 30 days. Assessment was done on the basis of symptomatic relief and change in the degree of SLR test after treatment. Observation: Dasmooladi Niruha Basti and Rasaraj Rasa yielded symptomatic relief and increased the degree of SLR test after treatment. The overall effect of the treatment in all patients suggested that, complete cure was not in any patient. Three patients were markedly improved, and seven patients were moderately improved. None of patients remained unchanged. Conclu-sion: On the basis of result obtained, it can be concluded that Dasmooladi Niruha Basti and Rasaraj Rasa can be used as an effective treatment in the management of Gridhrasi (sciatica).

  7. 7

    المؤلفون: Mishra Meenu, Shivhare Shwetal

    المصدر: International Ayurvedic Medical Journal. :2453-2457

    الوصف: Introduction: Transverse Myelitis is an acute, usually monophasic, demyelinating disorder affecting the spinal cord. It is usually thought to be post infectious in origin. It occurs at any age and present with a subacute paraparesis with a sensory level, accompanied by severe pain in the neck or back at the onset. The annual incidence of Transverse Myelitis ranges from 1.34 to 4.60 cases per million. In Ayurveda there is no description of a single disease which can exactly resemble with Transverse Myelitis. It can be correlated with Adhrangghata, which comes under Vatavyadhi. Aim: To study the effect of Panchkarma management with Physiotherapy in Transverse Myelitis and to find out effective Panchkarma management in Transverse Myelitis. Material & Methods: A 30-year-old male patient Vikas Dubey was visited unit OPD 31767 Kayachikitsa Govt. Ayurveda Hospital Bhopal. On 3rd June 2019 presented with Spastic Paraplegia, had involuntary movement in bilateral lower limbs along with moderate pain off and on and irregular bladder bowel movements. The patient was treated with Panchkarma along with Physiotherapy for 76 days. Assessment was done on the basis of symptomatic relief. Observation: The Panchkarma procedures along with physiotherapy yielded improvement in sensory & motor functions of patient. Conclusion: On the basis of result obtained, it can be concluded that Panchkarma along with physiotherapy can be used as effective treatment in management of Transverse Myelitis.

  8. 8

    المصدر: INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH. :1-3

    الوصف: Background: The skin or the integument is the external organ that protects against mechanical trauma, UV light and infections. The prevalence of skin diseases in India is 10 to 12% of the total population with psoriasis being the major contributor, in India it ranges from 0.44% to 2.8%. In Ayurveda all skin diseases come under the concept of Kushta. Psoriasis has a high resemblance with Ekkushta, which is the type of Kshudrakushta (less severe form of the Kushta). Skin diseases considered as Pitta Doshaja and Rakta Dhatu Pradoshaja Vikara. Acharya Charaka stated that Virechana is the great treatment for Pitta predominance diseases. Aim: To study the role of Virechana Karma in the management of Ekkushta (Psoriasis). Material and Methods: A single group of 5 diagnosed patients of Ekkushta (Psoriasis) were registered at the Kayachikitsa OPD of Pt. Khushilal Sharma Govt. (Auto.) Ayurvede Hospital Bhopal. The patients were treated with Virechana Karma. Duration of study is 21 days and follow up after completion of trial every week for 1 month. Assessment was done on the basis of symptomatic relief after treatment. Observation: The overall effect of the Virechana Karma in all patients suggested that, complete cure was not in any patient. One patient was mild improved, one patient was markedly improved and three patients were moderately improved. None of patients remained unchanged. Conclusion On the basis of this clinical trial it can be concluded that Virechana Karma works effectively in the management of psoriasis.

  9. 9

    المصدر: Cancer Research. 80:PD4-07

    الوصف: Background: Intravenous pertuzumab (P IV) + trastuzumab (H IV) + chemotherapy (CT) improves outcomes in patients (pts) with HER2-positive breast cancer, compared with H + CT.A new subcutaneous (SC) formulation, for the first time combining two monoclonal antibodies, P + H, with recombinant human hyaluronidase in one vial, was developed. This ready-to-use fixed-dose combination (PH FDC) is administered subcutaneously into the thigh over 5-8 minutes. The dose of H SC was confirmed in the phase III HannaH trial (NCT00950300) and the dose of P SC was established in a phase Ib study (NCT02738970). We report the first results from FeDeriCa (NCT03493854), which was designed to assess the pharmacokinetics, efficacy, and safety of this novel SC PH FDC compared with H IV + P IV in pts with HER2-positive early breast cancer in the neoadjuvant-adjuvant setting. Methods: Pts with centrally confirmed HER2-positive invasive breast cancer (tumor >2 cm, or node-positive disease; Stage II-IIIC) were randomized 1:1 to receive 8 cycles of CT in the neoadjuvant setting with H IV (loading dose 8 mg/kg, maintenance 6 mg/kg) + P IV (loading dose 840 mg, maintenance 420 mg) (Arm A) or CT per Arm A + PH FDC (loading dose 1200 mg P SC/600 mg H SC, maintenance 600 mg each; Arm B) administered q3w during cycles 5-8. CT was investigator’s choice of either 4 cycles of dose-dense doxorubicin + cyclophosphamide q2w → 4 cycles of weekly paclitaxel (total: 12 weeks), or 4 cycles of doxorubicin + cyclophosphamide q3w → 4 cycles of docetaxel q3w. Post-surgery, pts continued anti-HER2 treatment per randomization to complete 18 cycles. The primary objective was noninferiority (NI) of the pre-dose cycle 8 P serum trough concentration (Ctrough) within the PH FDC versus P IV (NI margin for the lower bound of the 90% confidence interval [CI] of the geometric mean ratio [GMR]: ≥0.8). Key secondary objectives were NI of pre-dose cycle 8 H Ctrough within the PH FDC versus H IV, total pathologic complete response in the breast and axilla (ypT0/is, ypN0; tpCR), and safety (primary cardiac events were defined as heart failure [New York Heart Association III + IV] with significant left ventricular ejection fraction [LVEF] decline; cardiac death. Secondary cardiac events were defined as LVEF decline ≥10% from baseline to below 50% and confirmed LVEF decline). Results: Five-hundred pts were randomized (252 to Arm A, 248 to Arm B - ITT and safety populations) from 06/14/18-12/24/18 at 122 sites. At clinical cutoff (07/04/19), 242 pts (96.0%) in Arm A and 234 (94.4%) in Arm B completed the neoadjuvant treatment phase. Baseline pt demographics and disease characteristics were well balanced between arms.The study met its primary endpoint: P GMR was 1.22 (90% CI 1.14-1.31) with the lower limit of the 90% CI being above the prespecified NI margin of 0.8. H GMR was 1.33 (90% CI 1.24-1.43), meeting the NI criteria. tpCR rates were comparable between arms (59.5%; 95% CI 53.2-65.6 in Arm A and 59.7%; 95% CI 53.3-65.8 in Arm B) and were similar to other P + H + CT trials. Overall safety, including cardiac safety, was comparable between arms (Table). Safety was as expected for P + H + CT trials. Conclusions: SC PH FDC demonstrated noninferior pre-dose cycle 8 P + H Ctrough to that of P IV + H IV, with comparable efficacy and safety. PH FDC offers a faster and simpler method of P + H administration for HER2-positive breast cancer. Pts, %Arm A n = 252Arm B n = 248Any AE in >50% of pts99.6100Alopecia70.277.0Nausea60.358.9Diarrhea55.258.5Grade ≥352.848.8Serious17.916.1CardiacPrimary00.8Secondary3.61.6Asymptomatic LVEF decline needing treatment/discontinuation4.02.0Death0.4*0.4** Unrelated to HER2 treatment Citation Format: Antoinette R Tan, Seock-Ah Im, Andre Mattar, Ramon Colomer, Daniil Stroyakovskii, Zbigniew Nowecki, Michelino De Laurentiis, Jean-Yves Pierga, Kyung Hae Jung, Christian Schem, Sarah Heeson, Mahesh Shivhare, Whitney P. Kirschbrown, Eleonora Restuccia, Tanja Badovinac Crnjevic, Christian Jackisch. Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: Primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr PD4-07.

  10. 10

    المصدر: Journal of Chitwan Medical College. 9:34-42

    الوصف: Background: Temporomandibular disorders (TMDs) comprise of a variety of clinical signs and symptoms such as joint sounds, muscle tenderness, joint tenderness, deviation, deflection, pain on mouth opening, protru­sive, lateral movement and limited mouth opening which can be the re­sult of trauma, stress, gum chewing, hard food biting habits, bruxism, long dental appointment. This study was aimed to determine the prevalence of temporomandibular disorders in Nepalese population in Eastern Nepal. Methods: The study was performed from May 2018 to Oct 2018. All the patients who came to the Department of Oral Medicine and Radiology, Nobel Medical College and Teaching Hospital (NMCTH) and health camps in Eastern part of Nepal were included. The self-administered questions were asked to the subjects about demographic data, different signs and symptoms of TMDs and etiological factors responsible for it. Results: More than two thirds of the study sample (83.96%) in the present study had one or more clinical signs and symptoms of TMDs. Deviation of mandible on mouth opening and clicking sound made up the highest per­centage. Females were reported to have significantly higher prevalence of TMDs signs and symptoms than male. Disc displacement was the most prevalent disorder followed by myofascial pain and degenerative joint dis­order. Conclusions: The results of this study show that a significant percentage of the population has signs and symptoms of TMDs. Measures should be taken to prevent and treat TMDs in this part of the world.